Emergent BioSolutions

Expanding Licensure of BioThrax Globally

Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries

Protecting You From Public Health Threats

Our mission is to protect and enhance life

Prepare. Prevent. Protect.

We make medical countermeasures that address natural, accidental and intentional public health threats. Our products target biological and chemical threats, as well as emerging infectious diseases.

Strengthening Our Anthrax Franchise

Emergent BioSolutions Completes Acquisition of Raxibacumab from GlaxoSmithKline

Read the full press release

Fighting Emerging Infectious Diseases

Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus

READ THE FULL PRESS RELEASE

Expanding Our Portfolio of Medical Countermeasures

Emergent BioSolutions Completes Acquisition of ACAM2000 Vaccine Business from Sanofi

Read the full press release

Explore more stories Scroll down